The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells

Biochemical and Biophysical Research Communications

Volumn 398, Issue 3, 2010, Pages 372-376

  Schopperle, William M ^a   Lee, Jung M ^b   DeWolf, William C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Cancer; Embryonal carcinoma; Glucose transporter; Pluripotent stem cell; Podocalyxin

Indexed keywords

BIOLOGICAL MARKER; CELL MARKER; CELL PROTEIN; CELL SURFACE PROTEIN; GLUCOSE TRANSPORTER 3; GLYCOPROTEIN; PODOCALYXIN; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; EMBRYONAL CARCINOMA; EMBRYONAL CARCINOMA STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PHENOTYPE; PLURIPOTENT STEM CELL; PRECIPITATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; REGULATORY MECHANISM; RNA INTERFERENCE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GLUCOSE TRANSPORTER TYPE 3; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS; RNA, SMALL INTERFERING; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955278752     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.074     Document Type: Article

References (39)

1. Kershaw D.B., Beck S.B., Wharram B.L., Wiggins J.E., Goyal M., Thomas P.E., Wiggins R.C. Molecular cloning and characterization of human podocalyxin-like protein. J. Biol. Chem. 1997, 272:15708-15715.
2. Nielsen J.S., McNagny K.M. Novel functions of the CD34 family. J. Cell Sci. 2008, 121:3683-3692.
3. Sassetti C., Zante A.V., Rosen S.D. Identification of endoglycan, a member of the CD34/podocalxyin family of sialomucins. J. Biol. Chem. 2000, 275:9001-9010.
4. Kerjaschki D., Sharkey D.J., Farquhar M.G. Identification and characterization of podocalyxin: the major sialoprotein of the renal glomerular epithelial cell. J. Cell Biol. 1984, 98:1591-1596.
5. + exchange regulatory factor-2. Am. J. Physiol. Renal Physiol. 2001, 282:1129-1139.
6. Takeda T., McQuistan T., Orlando R.A., Farquhar M.G. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J. Clin. Invest. 2001, 108:289-301.
7. McNagny K.M., Pettersson I., Rossi F., Flamme I., Shevchenko A., Mann M., Graf T. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J. Cell Biol. 1997, 138:1395-1407.
8. Hara T., Nakano Y., Tanaka M., Tamura K., Sekiguchi T., Minehata K., Copeland N.B., Jenkins N.A., Okabe M., Kogo H., Mukouyama Y., Miyajima A. Identification of podocalyxin-like protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region. Immunity 1999, 11:567-578.
9. Kerosuo L., Juvonen K., Alitao R., Gylling M., Kerjaschki D., Miettinen A. Podocalyxin in human haematopoietic cells. B. J. Haematol. 2003, 124:809-818.
10. Doyonnas R., Nielsen J.S., Chelliah S., Drew E., Hara T., Miyajima A., McNagny K.M. Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood 2005, 105:4170-4178.
11. Sassetti C., Tangemann K., Singer M.S., Kershaw D.B., Rosen S.D. Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J. Exp. Med. 1998, 187:1965-1975.
12. Schopperle W.M., Kershaw D.B., DeWolf W.C. Human embryonal carcinoma tumor antigen, GP200/GCTM-2 is podocalyxin. Biochem. Biophys. Res. Commun. 2003, 300:285-290.
13. Schopperle W.M., DeWolf W.C. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cell 2007, 25:723-730.
14. Yu J., Thomson J.A. Pluripotent stem cell lines. Genes Develop. 2008, 22:1987-1997.
15. Richards M., Tan S., Tan J., Chan W., Bongso A. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 2004, 22:51-64.
16. Bhattacharya B., Miura T., Brandenberger R., Mejido J., Luo Y., Yang A.X., Joshi B.H., Ginis I., Thies R.S., Amit M., Lyons I., Condie B.G., Itskovitz-Eldor J., Rao M.S., Puri R.K. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood 2004, 103:2956-2964.
17. Zeng X., Miura T., Luo Y., Bhattacharya B., Condie B., Chen J., Lyons I., Mejido J., Puri R.K., Rao M.S., Freed W.J. Properties of pluripotent human embryonic stem cells BGO1 and BGO2. Stem Cells 2004, 22:292-312.
18. Hayman M.W., Przyborski S.A. Proteomic identification of biomarkers expressed by human pluripotent stem cells. Biochem. Biophys. Res. Commun. 2004, 316:918-923.
19. Sizemore S., Cicek M., Sizemore N., Ng K.P., Casey Graham Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 2007, 67:6183-6191.
20. Casey G., Neville P.J., Liu X., Plummer S.J., Cicek M.S., Krumroy L.M., Curran A.P., McGreevy M.R., Catalona W.J., Klien E.A., Witte J.S. Podocalxyin variants and risk of prostate cancer and tumor aggressiveness. Human Mol. Gen. 2006, 15:735-741.
21. Heukamp L.C., Fischer H.P., Schirmarher P., Chen X., Breuhahn K., Nicolay C., Buttner R., Gutgemann I. Podocalyxin-like protein 1 expression in primary hepatic tumors and tumor-like lesions. Histopath 2006, 49:242-247.
22. Koch L., Zhou H., Ellinger J., Biermann K., Holler T., von Rucker A., Buttner R., Gutgemann I. Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Human Path. 2008, 39:1597-1605.
23. Kelley T., Huntsman D., McNagny K.M., Roskelley C.D., His E.D. A marker of blast in acute leukemia. Hematopathology 2005, 124:134-142.
24. Chen X., Higgins J., Cheung S., Li R., Mason V., Montogomery K., Fan S., van de Rijn M., So S. Novel endothelial cell markers in hepatocellular carcinoma. Mod. Path. 2004, 17:1198-1210.
25. Ito T., Make N., Hazeki O., Sasaki K., Nedooki M. Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines. Cell Biol. Inter. 2007, 31:1518-1524.
26. Stanhope-Baker P., Dessler P.M., Li W., Agarwal M.L., Williams B.R.G. The wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. J. Biol. Chem. 2004, 279:33575-33585.
27. Yasuoka H., Tsupimoto M., Hirokawa M., Tori M., Nakahara M., Miyauchi A., Kodama R., Sanke T., Nakamura Y. Podocalxyin expression in undifferentiated thyroid carcinomas. J. Clin. Pathol. 2008, 61:1228-1229.
28. Somarsiri A., Nielsen J.S., Makretxov N., McCoy M.L., Prentice L., Gilks C.B., Chis S.K., Gelmon K.A., Kershaw D.B., Huntsman D.G., McNagny K.M., Roskelley C.D. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Can. Res. 2004, 64:5068-5073.
29. Ney J.T., Zhou H., Sipos B., Buttner R., Chen X., Kloppel G., Gutgemann I. Podocalyxin-like protein expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Human Pathol. 2007, 38:359-364.
30. Hayatsu N., Kaneko M.K., Mishima K., Nishikawa R., Matsutani M., Price J.E., Kato Y. Podocalyxin expression in malignant astrocytic tumors. Biochem. Biophys. Res. Commun. 2008, 374:394-398.
31. Riccioni R., Calzolari A., Biffoni M., Senese M., Riti V., Petrucci E., Pasquini L., Cedrone M., Lo-Coco F., Diverio D., Foa R., Peschle C., Testa U. Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mole. Dis. 2006, 37:218-225.
32. Solter D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat. Rev. Gen. 2006, 7:319-326.
33. Macheda M.L., Rogers S., D Best J. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202:654-662.
34. Larrucea S., Butta N., Arias-Salgado E.G., Alonso-Martin S., Ayuso M.S., Parrilla R. Expression of podocalyxin enhances the adherence, migration and intercellular communication of cells. Exp. Cell Res. 2008, 314:2004-2015.
35. Tan H.L., Fong W.J., Lee E.H., Yap M., Choo A. mAb84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009, 27:1792-1801.
36. Schmidt S., Hommel A., Gawlik V., Augustin R., junicke N., Florian S., Richter M., Walther D.J., Montag D., Joost H.G., Schurmann A. Essential role of glucose transporter Glut3 for post-implantation embryonic development. J. Endocrinol. 2009, 200:23-33.
37. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
38. Weihua Z., Tsan R., Huang W., Wu Q., Chiu C., Fidler I.J., Hung M. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
39. Wegner B., Al-Momany A., Kulak S., Kozlowski K., Obeidat M., Jahroudi N., Paes J., Berryman M., Ballermann B.J. CLIC5A, a component of the ezrin-podocalyxin complex in glomeruli, is a determinant of podocyte integrity. Am. J. Physiol. Renal Physiol. 2010, 298:1492-1503.